Normal-Weight Diabetes: Adipocyte-directed Therapy With Pioglitazone or Tirzepatide

This study is looking for women aged 30-70 with type 2 diabetes who are at a normal weight (BMI between 19 and 24.9 kg/m²). It aims to understand how fat cells (adipocytes) and fat distribution differ in normal-weight individuals with diabetes compared to those with diabetes who are overweight, and those without diabetes. Researchers will test if medications called pioglitazone or tirzepatide can improve how your body uses insulin (insulin resistance), how your fat cells work, and how fat is stored. Success would mean seeing improvements in insulin resistance, fat cell function, and fat storage. The study is currently unclear on its recruitment status and plans to enroll 104 participants.

Study design
This is an interventional study, meaning participants will receive specific treatments. It aims to enroll 104 participants, but the phase is not specified.
What's involved
You would undergo insulin resistance testing, an OGTT (oral glucose tolerance test) with 5 blood draws, a fat biopsy, a DXA scan, and an abdominal MRI.
Compensation
Not stated in the trial record.
Follow-up
Primary endpoints are measured at baseline comparisons between groups, so specific follow-up duration after treatment is not clear.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06657209

Normal-weight Diabetes: Adipocyte-directed Therapy With Pioglitazone or Tirzepatide

Recruiting
PHASE4Ages 30–70InterventionalTreatment
Stanford University
~104 participants
Updated 2026-04-20 on ClinicalTrials.gov
What's tested:Insulin resistance testingOGTTFat biopsyDXA scanMRI1H-MRS

At a glance

Recruiting sites
1 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Insulin resistance in normal weight women with diabetes compared to those with no diabetes
Measured over Baseline measures comparison between the groups
+2 more outcomes measured
Diabetes Mellitus, Type 2
Diabetes
Type 2 Diabetes
Pre Diabetes
2 sites across 1 states
California2

Opens a ready-to-send draft in your own email app — review before sending.

  • Insulin resistance in normal weight women with diabetes compared to those with no diabetesBaseline measures comparison between the groups

    Insulin resistance will be measured by a Steady State Plasma Glucose test (SSPG). Results will be measured by glucose levels at steady state in mg/dL.

  • Adipocyte function in women with normal weight diabetes as compared with those without diabetesBaseline comparisons

    Adipocyte function will be measured as percent small adipocytes and peak diameter adipocytes from the fat biopsies.

  • Fat storage in women with normal weight diabetes compared to those without diabetesBaseline comparisons between the groups

    Fat storage will be measured by MRI. Quantification of subcutaneous and visceral abdominal fat will be obtained by MRI using a fat-water imaging sequence (parameters: IDEAL-IQ: 3D GRE, 160x160 matrix, 6 echoes, 4 degree flip angle, minimum TR = 7.3 ms, 28 slices, 10 mm slice thickness.